# US 2026/0007783 A1 · A 3E8.scFv.Cys-IR800 Conjugate Targeting TAG-72 in an Orthotopic colorectal cancer model

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0007783 A1
- Document ID: US20260007783A1
- Status: Published application
- Kind: A1
- Application number: 19/256,293
- Filed: 2025-07-01
- Published: 2026-01-08
- Earliest claimed: 2023-11-30
- Assignees: Ohio State Innovation Foundation
- Applicants: Ohio State Innovation Foundation
- Inventors: Michael F. Tweedle; Li Gong
- Web page: https://patentgrep.com/patent/US20260007783A1

## CPC

- A61K 49/0032: {Methine dyes, e.g. cyanine dyes}
- A61K 51/0459: {having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 49/0058: {Antibodies}
- A61K 49/006: {Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery}
- A61K 51/1045: {against animal or human tumor cells or tumor cell determinants}
- C07K 16/30: from tumour cells
- C07K 16/3092: {against tumour-associated mucins}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/524: CH2 domain
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/90: characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Disclosed are compositions are anti-TAG-72 imaging agents and methods of their usc.

## Claims

### Claim at position 1

1-18. (canceled)

### Claim 19

A method of monitoring recurrence of a cancer in a subject following surgical removal of said tumor the method comprising:
a. administering to a subject intraperitoneally an anti-tumor-associated glycoprotein 72 (TAG-72) imaging agent comprising the formula Y-R, wherein Y comprises an anti-TAG-72 binding moiety and R comprises a first detectable label; wherein the first detectable label “R” comprises any dicyanine dye that emits fluorescent light that is detectable on a clinical optical near infrared fluorescence-(NIRF) imager above 800 nm; wherein the dicyanin dye is selected from the group consisting of infrared (IR) dye800, AlexaFluor 790, ZW-800, Indocyanine Green, and S0456; wherein the anti-TAG-72 binding moiety comprises 3E8.scFv; and
b. monitoring for the presence of the detectable label of bound anti-TAG-72 binding moiety; wherein the presence of bound anti-TAG-72 binding moiety indicates a recurrent cancer.

### Claim 20 (depends on 19)

The method of claim 19, further comprising treating the recurrent cancer.

### Claim 21 (depends on 20)

The method of claim 20, wherein the cancer treatment comprises guiding the surgical removal of the tumor using optical surgical navigation wherein the combination of the 3E8.scFv and the detectable label causes the signaling intensity of the anti-tumor-associated glycoprotein 72 (TAG-72) imaging agent in the liver and tumor tissue to differ.

### Claim 22 (depends on 19)

The method of claim 19, wherein the anti-TAG-imaging agent comprises a second detectable label and wherein the second label is a radiolabel

### Claim 23

A method of monitoring the progression of a cancer in a subject the method comprising:
a. administering to a subject intraperitoneally an anti-tumor-associated glycoprotein 72 (TAG-72) imaging agent comprising the formula Y-R, wherein Y comprises an anti-TAG-72 binding moiety and R comprises a first detectable label; wherein the first detectable label “R” comprises any dicyanine dye that emits fluorescent light that is detectable on a clinical optical near infrared fluorescence-(NIRF) imager above 800 nm; wherein the dicyanin dye is selected from the group consisting of infrared (IR) dye800, AlexaFluor 790, ZW-800, Indocyanine Green, and S0456; wherein the anti-TAG-72 binding moiety comprises 3E8.scFv; and
b. monitoring for a change in the level of the detectable label of bound anti-TAG-72 binding moiety; wherein an increase in the level of detectable bound anti-TAG-72 binding moiety indicates a the cancer is increasing, no change in the level of detectable bound anti-TAG-72 binding moiety indicates the cancer is not progressing; and a decrease in the level of detectable bound anti-TAG-72 binding moiety indicates the cancer is shrinking.

### Claim 24 (depends on 23)

The method of claim 23, wherein when the level of detectable bound anti-TAG-72 binding moiety increases, the method further comprises treating the cancer.

### Claim 25 (depends on 24)

The method of claim 24, wherein the cancer treatment comprises guiding the surgical removal of the tumor using optical surgical navigation wherein the combination of the 3E8.scFv and the detectable label causes the signaling intensity of the anti-tumor-associated glycoprotein 72 (TAG-72) imaging agent in the liver and tumor tissue to differ.

### Claim 26 (depends on 23)

The method of claim 23, wherein the anti-TAG-imaging agent comprises a second detectable label and wherein the second label is a radiolabel.

### Claim 27 (depends on 23)

The method of claim 23, wherein the method is being performed following the commencement of treatment or following surgical removal of said tumor.

### Claim 28 (depends on 23)

The method of claim 23, wherein when the level of detectable bound anti-TAG-72 binding moiety increases, the method further comprises modifying the treatment of the cancer.
